KalVista Pharmaceuticals will present new clinical data for sebetralstat, its investigational oral plasma kallikrein inhibitor for hereditary angioedema (HAE), at several major medical conferences throughout 2025. The presentations will showcase findings from ongoing trials that could support sebetralstat's potential approval as the first oral, on-demand treatment for HAE attacks.
Key Conference Presentations
At the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress in San Diego (February 28-March 3, 2025), KalVista will present six abstracts. Notable presentations include an interim analysis from the KONFIDENT-S trial examining sebetralstat's effectiveness for laryngeal HAE attacks and a pooled analysis of on-demand treatment data in adolescents from both KONFIDENT and KONFIDENT-S studies.
The company will also present at two concurrent conferences from May 29-June 1, 2025: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference in Palm Beach, Florida. These presentations will include new findings on sebetralstat's potential to rapidly relieve symptoms and halt progression of HAE attacks, including mucosal and severe cases.
Clinical Trial Insights
The presentations will feature data from the KONFIDENT-S trial, including effectiveness results for mucosal hereditary angioedema attacks and analysis of time to end of progression of HAE attacks treated with sebetralstat. Additional data will examine sebetralstat's performance in specific patient populations, including adolescents and older adults.
One presentation will address anxiety associated with hereditary angioedema attacks using results from the phase 3 KONFIDENT trial. The company will also present survey results from Italy, the US, UK, and France examining anxiety in patients using injectable on-demand treatments for HAE attacks.
Regulatory Status and Market Potential
Sebetralstat is currently under regulatory review by the U.S. FDA, with a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2025. KalVista has also completed Marketing Authorization Applications to the European Medicines Agency and multiple other global regulatory authorities.
The drug is being developed for individuals aged 12 and older, with ongoing studies exploring its use in children aged 2 to 11 through the KONFIDENT-KID trial. If approved, sebetralstat has the potential to become what KalVista describes as "the foundational therapy for HAE management worldwide."
Addressing Unmet Medical Need
Hereditary angioedema is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.
Currently, all approved on-demand treatment options require either intravenous or subcutaneous administration. Sebetralstat's oral formulation could address significant treatment barriers, as evidenced by several presentations examining delays in on-demand treatment and associated barriers reported across different healthcare systems.
The upcoming presentations will provide healthcare professionals and researchers with comprehensive data on sebetralstat's clinical performance across various patient populations and attack types, potentially supporting its regulatory approval and future clinical use in HAE management.
